

Rec'd PCT/PTO

7 JUL 2005

#5

Express Mail No.: EV 452 775 753 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Senter et al.

Confirmation No. 7034

Application No.: 10/522,911 (U.S. National
Stage of PCT/US03/24209, filed July 31, 2003)

Group Art Unit: TBA

Filed: July 31, 2003

Examiner: TBA

For: DRUG CONJUGATES AND THEIR
USE FOR TREATING CANCER, AN
AUTOIMMUNE DISEASE OR AN
INFECTIOUS DISEASE

Attorney Docket No.: 9632-093-999
(CAM: 407517-999091)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to References **A01-A25**, **B01-B10** and **C01-C14**, which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Copies of references **B01-B10** and **C01-C14** are submitted herewith. Copies of references **A01-A25** (each being a U.S. patent or patent publication) are not submitted herewith pursuant to waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent or patent publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 U.S.C. § 371 after June 30, 2003.

Applicants request that the Examiner review the references identified on the attached Form PTO-1449, and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b)(3), before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, the Commissioner is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: July 7, 2005


Adriane M. Antler (Reg. No. 32,605)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

| | | |
|---|---|--------------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 9632-093-999 | APPLICATION NO. 10/522,911 |
| | APPLICANT Senter et al. | |
| | FILING DATE July 31, 2003 | GROUP TBD |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----|-----------------|------------|-------------------|-------|----------|-------------------------------|
| /CB/ | A01 | 4,414,205 | 11/08/1983 | Pettit | | | |
| /CB/ | A02 | 4,816,444 | 03/28/1989 | Pettit et al. | | | |
| /CB/ | A03 | 4,879,278 | 11/07/1989 | Pettit et al. | | | |
| /CB/ | A04 | 4,978,744 | 12/18/1990 | Pettit et al. | | | |
| /CB/ | A05 | 5,410,024 | 04/25/1995 | Pettit et al. | | | |
| /CB/ | A06 | 5,521,284 | 05/28/1996 | Pettit et al. | | | |
| /CB/ | A07 | 5,530,097 | 06/25/1996 | Pettit et al. | | | |
| /CB/ | A08 | 5,554,725 | 09/10/1996 | Pettit | | | |
| /CB/ | A09 | 5,599,902 | 02/04/1997 | Pettit et al. | | | |
| /CB/ | A10 | 5,635,483 | 06/03/1997 | Pettit et al. | | | |
| /CB/ | A11 | 5,654,399 | 08/05/1997 | Sakakibara et al. | | | |
| /CB/ | A12 | 5,663,149 | 09/02/1997 | Pettit et al. | | | |
| /CB/ | A13 | 5,665,860 | 09/09/1997 | Pettit et al. | | | |
| /CB/ | A14 | 5,741,892 | 04/21/1998 | Barlozzari et al. | | | |
| /CB/ | A15 | 5,767,236 | 06/16/1998 | Kim et al. | | | |
| /CB/ | A16 | 5,767,237 | 06/16/1998 | Sakakibara et al. | | | |
| /CB/ | A17 | 5,780,588 | 07/14/1998 | Pettit et al. | | | |
| /CB/ | A18 | 5,840,699 | 11/24/1998 | Sakakibara et al. | | | |
| /CB/ | A19 | 6,004,934 | 12/21/1999 | Sakakibara et al. | | | |
| /CB/ | A20 | 6,034,065 | 03/07/2000 | Pettit et al. | | | |
| /CB/ | A21 | 6,124,431 | 09/26/2000 | Sakakibara et al. | | | |
| /CB/ | A22 | 6,162,930 | 12/19/2000 | Pinney et al. | | | |
| /CB/ | A23 | 6,239,104 | 05/29/2001 | Pettit et al. | | | |
| /CB/ | A24 | 6,342,221 | 01/29/2002 | Thorpe et al. | | | |
| /CB/ | A25 | 2001/0018422 | 08/30/2001 | Ritter et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|------|-----|-----------------|------------|-----------------------------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| /CB/ | B01 | WO 93/03054 | 02/18/1993 | PCT (with English abstract) | | | | |
| /CB/ | B02 | WO 95/09864 | 04/13/1995 | PCT (with English abstract) | | | | |
| /CB/ | B03 | WO 96/14856 | 5/23/1996 | PCT | | | | |
| /CB/ | B04 | WO 96/33212 | 10/24/1996 | PCT (with English abstract) | | | | |
| /CB/ | B05 | WO 01/18032 | 03/15/2001 | PCT | | | | |
| /CB/ | B06 | WO 2004/010957 | 02/05/2004 | PCT | | | | |
| /CB/ | B07 | EP 0 598 129 | 05/25/1994 | EPO | | | | |

| | | | | | | | | |
|------|-----|--------------|------------|-----|--|--|--|--|
| /CB/ | B08 | EP 0 695 757 | 02/07/1996 | EPO | | | | |
| /CB/ | B09 | EP 0 695 758 | 02/07/1996 | EPO | | | | |
| /CB/ | B10 | EP 0 695 759 | 02/07/1996 | EPO | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|------|-----|--|
| /CB/ | C01 | Bowman et al. 1950, "N-substituted amino-acids. Part I. A new method of preparation of dimethylamino-acids," J. Chem. Soc.:1342-1351 |
| /CB/ | C02 | Miyazaki et al., 1995, "Synthesis and antitumor activity of novel dolastatin 10 analogs," Chem. Pharm. Bull. (Tokyo) 43(10):1706-1718 |
| /CB/ | C03 | Pettit et al., 1995, "Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications," Anticancer Drug Des. 10(7):529-544 |
| /CB/ | C04 | Pettit, 1998, "Antineoplastic agents 365. Dolastatin 10 SAR probes," Anticancer Drug Des. 13(4):243-277 |
| /CB/ | C05 | Petit et al., 1996, "Dolastatins. 23: Stereospecific synthesis of dolaisoleuine," J. Chem Soc. Perkin. Trans. 1:853-858 |
| /CB/ | C06 | Pettit et al., 1996, "Dolastatins 24. Synthesis of (-)-dolastatin 10. X-ray molecular structure of N,N-dimethylvalyl-valyl-dolaisoleuine, tert-butyl ester," J. Chem. Soc. Perk Trans. 1:859-863 |
| /CB/ | C07 | Pettit et al., 1994, "The Dolastatins. 17. Synthesis of dolaproine and related diastereoisomers," J. Org. Chem. 59(21):6287-6295 |
| /CB/ | C08 | Pettit et al., 1996, "The Dolastatins. 18. Stereospecific synthesis of dolaproine," Synthesis 6:719-725 |
| /CB/ | C09 | Pettit et al., 1994, "The Dolastatins. 19. Synthesis of dolaisoleuine," J. Org. Chem. 59(7):1796-1800 |
| /CB/ | C10 | Pettit, 1997, "The Dolastatins," (reprint) Springer-Verlag, New York 70:1-79 |
| /CB/ | C11 | Shioiri et al., 1993, "Stereoselective synthesis of dolastatin 10 and its congeners," Tetrahedron 49(9):1913-1924 |
| /CB/ | C12 | Toki et al., "Cures and regressions of established tumor xenographs with monoclonal antibody," 223 rd ACS Meeting, Orlando FL, April 7-11, 2002, Abstract 147 |
| /CB/ | C13 | Tomioka et al., 1991, "An expeditious synthesis of dolastatin 10," Tetrahedron Letters 32(21):2395-2398 |
| /CB/ | C14 | International search report of International Application No. PCT/US03/24209, 16 Apr 2004 |

EXAMINER /Christina Bradley/ (04/22/2008)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.